Attached files
| file | filename |
|---|---|
| EX-32 - EXHIBIT 32 - Innoviva, Inc. | inva-20201231xex32.htm |
| EX-31.2 - EXHIBIT 31.2 - Innoviva, Inc. | inva-20201231xex31d2.htm |
| EX-31.1 - EXHIBIT 31.1 - Innoviva, Inc. | inva-20201231xex31d1.htm |
| EX-23.2 - EXHIBIT 23.2 - Innoviva, Inc. | inva-20201231xex23d2.htm |
| EX-23.1 - EXHIBIT 23.1 - Innoviva, Inc. | inva-20201231xex23d1.htm |
| 10-K - 10-K - Innoviva, Inc. | inva-20201231x10k.htm |
Exhibit 21.1
LIST OF SUBSIDIARIES
Name |
| Jurisdiction |
| Ownership Interest |
|
Theravance Respiratory Company, LLC | | Delaware | | (1) | |
Advanced Medicine East, Inc | | Delaware | | 100 | % |
Pulmoquine Therapeutics, Inc. | | Delaware | | (2) | |
Innoviva Strategic Partners LLC | | Delaware | | 100 | % |
Innoviva Royalty Sub LLC | | Delaware | | 100 | % |
Innoviva TRC Holdings LLC | | Delaware | | 100 | % |
Innoviva Strategic Opportunities LLC | | Delaware | | 100 | % |
(1) The Company owns 15% of the economic interests in Theravance Respiratory Company, LLC ("TRC") but has the power to direct TRC's economically significant activities and the obligation to absorb losses of, or the right to receive benefits from them. Accordingly, TRC's financial results are consolidated in the Company’s financial statements.
(2) As of December 31, 2020, the Company owned 91% of the outstanding equity and 56% of the voting power in Pulmoquine Therapeutics, Inc. ("Pulmoquine"). Pulmoquine's financial results are consolidated in the Company’s financial statements.